Back to Search
Start Over
Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation.
- Source :
-
Dermatologic Therapy . Nov/Dec2017, Vol. 30 Issue 6, pn/a-N.PAG. 4p. - Publication Year :
- 2017
-
Abstract
- Pityriasis rubra pilaris (PRP) is a rare, difficult to treat papulosquamous disorder that responds variably to retinoids and immunosuppression. Successful use of biologics for treating PRP has been described in the literature by case reports and a limited number of case series. To provide additional data, we retrospectively analyzed cases of PRP treated with biologics at our institution. We identified seven patients with a clear diagnosis of PRP treated with adalimumab, etanercept, and/or ustekinumab at our institution from January 1, 2014 to April 1, 2017. Six of seven patients had type I, adult acquired PRP, and one had type V atypical juvenile PRP. In response to tumor necrosis factor (TNF)-α inhibition, two patients had marked responses (>75% improvement in involved body surface area), while three patients failed to show any improvement on a TNF-α inhibitor. In two cases of PRP refractory to TNF-α inhibition, ustekinumab resulted in a partial response (<75% improvement) in one patient and no response in the other. Compared to other published data, our cohort was substantially more resistant to treatment with biologics, a finding which may provide valuable perspective for dermatologists managing refractory PRP in the future. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 13960296
- Volume :
- 30
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- Dermatologic Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 126564606
- Full Text :
- https://doi.org/10.1111/dth.12559